ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing
September 17th, 2024, Tromsø, Norway — ArcticZymes Technologies (OSE: AZT) has released a timely whitepaper in Select Science titled "Efficient Chromatin Removal in Viral Vector Manufacturing Using Salt-Active Nucleases." As global attention on salt-active nucleases increases, this whitepaper reinforces ArcticZymes' leadership by offering crucial insights that help viral vector manufacturers optimize their downstream processing (DSP) and make informed decisions.
The peer-reviewed studies cited in this paper will help leverage rising interest about Salt Active Nucleases and guide the spotlight to ArcticZymes' as the pioneer. This will bring added awareness to products like M-SAN HQ which, these studies show, demonstrate superior results for viral vector manufacturing, particularly under physiological salt conditions.
The referenced studies demonstrate how M-SAN HQ efficiently fragments chromatin, accelerating digestion times and leading to cleaner viral vector products with fewer DSP steps. These advantages not only increase DSP efficiency and yield but also significantly reduce costs—crucial benefits for today’s fast-growing therapeutic virus manufacturing sector.
As the tide of interest in salt-active nucleases rises, ArcticZymes is well-positioned to capitalize, with its cutting-edge enzyme solutions poised to elevate the company’s influence in the evolving bioprocessing landscape.
Commenting on the release, Michael B. Akoh, CEO of ArcticZymes Technologies, said: "The increasing focus on salt-active nucleases offers a significant opportunity for ArcticZymes to showcase our leadership in the field. This whitepaper underscores how our innovative solutions, such as M-SAN HQ, can revolutionize viral vector manufacturing, helping our partners lower costs and scale their operations more efficiently. At ArcticZymes, we understand that bioprocessing is complex, and a 'one size fits all' approach doesn’t work. That’s why we’ve created two specialized nucleases—M-SAN HQ for physiological salt conditions and SAN HQ GMP for high salt environments. Together, these enzymes deliver a complete solution for the entire viral vector production process."
To view the full white paper as published in Select Science click here: https://cdn.prod.website-files.com/64d5ee31f6ef966121388e81/66e9a2fcf995c33cd0554eb3_SAN%20Paper%20A4%202024-09.pdf
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15
CFO, Børge Sørvoll Tel: +47 95 29 01 87
ir@arcticzymes.com
About ArcticZymes Technologies ASA:
ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who developing therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customer’s lives easier by unlocking new solutions to enhance quality of life and create a more sustainable, healthy world.